SelectQuote, Inc. (NYSE: SLQT) approved 18% fewer Medicare Advantage policies in its first fiscal quarter of 2027 than in the same period a year earlier, and total revenue fell to $280 million from $329 million. The lifetime value of commissions per approved Medicare Advantage policy, however, rose 16% year on year, from $769 to $890.
That gap between falling volume and rising per-policy value is worth examining heading into the Medicare Annual Enrollment Period, which runs through December 7, 2026.
SelectQuote’s LTV increase reflects conditions across the entire Medicare distribution channel, rather than company-specific performance. For the 2027 plan year, approximately 2.8 million general-enrollment Medicare Advantage members, representing about 13% of 2026 enrollment, are in plans that will not be available for 2027, according to Oliver Wyman’s November 2026 analysis of CMS plan landscape data.
Eleven insurers that offered individual Medicare Advantage coverage in 2026 are leaving that market entirely for 2027, according to an analysis of CMS plan landscape data. When that volume of beneficiaries needs to find new coverage, carriers competing for re-enrollment spend more on distribution, and commission values move with that demand.
Aetna told marketing organizations it would not pay commissions on 123 Medicare Advantage plans across 33 states for the 2027 plan year, according to Medical Daily. The result is a bifurcated environment: higher LTV where carriers want volume, suppressed or zero commissions where they do not. SelectQuote’s trailing twelve-month revenue-to-customer-acquisition-cost multiple improved from 6.4x to 7x, which management cited on the earnings call as a measure of distribution efficiency in that environment.
The company’s response to these conditions has been to shrink deliberately. SelectQuote reduced its senior agent headcount going into AEP, betting that a smaller, tenured agent force would generate better per-unit economics than a larger but less experienced one. Chief executive officer Tim Danker said on the call that the company’s “tenured agent force is helping a highly-engaged Medicare beneficiary population find the right plans to meet their unique needs.”
The senior segment’s adjusted EBITDA loss narrowed from $21 million to $12.3 million year on year, suggesting the efficiency bet is paying off even as volume contracts.
A similar logic governs SelectQuote’s Healthcare Services segment, which houses its SelectRx home-delivery pharmacy. Revenue in the segment fell 16% to $186 million, partly because of reimbursement headwinds from the Inflation Reduction Act and partly because the company reduced SelectRx membership by 7%, from approximately 107,000 to 99,753, by tightening its member qualification criteria.
Adjusted EBITDA in the segment rose 56% to $11.2 million, and profitability per SelectRx member jumped 60%, from $67.10 to $107.60. The company is accepting lower revenue in exchange for a meaningfully better margin per member.
The life segment, meanwhile, reported an adjusted EBITDA margin of 17%, up from 12% a year ago, on revenue of $42.8 million. Final expense premiums fell 32% to $20.1 million, a steeper decline than term premiums, though the segment remained profitable overall.
SelectQuote maintained its full-year fiscal 2027 guidance of $1.35 billion to $1.45 billion in revenue and $90 million to $115 million in adjusted EBITDA, with operating cash flow expected to exceed $60 million.
SelectQuote is a named defendant in a federal False Claims Act case currently proceeding in the US District Court for the District of Massachusetts, United States of America ex rel. Andrew Shea v. eHealth, Inc. et al., Civil Action No. 21-cv-11777-DJC. The Department of Justice joined the case in May 2025, alleging that SelectQuote and two other large Medicare brokers, eHealth and GoHealth, received illegal kickback payments from carriers including Aetna, Humana, and Elevance Health, among others in exchange for steering beneficiaries into the insurers’ Medicare Advantage plans between 2016 and 2021.
SelectQuote has denied the allegations and said it intends to defend the case vigorously. Discovery is ongoing, with a September 2026 court order establishing the protocol for electronically stored information.
The disruption reshaping the 2027 Medicare Advantage market is simultaneously elevating commission values for the policies carriers want placed and eliminating commissions on the ones they do not. SelectQuote’s Q1 results put figures on both sides of that equation.
